4. Physiological significance of replacement therapy of dehydroepiandrosterone

Internal Medicine

Volumn 43, Issue 2, 2004, Pages 156-158

  Yanase, Toshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Aging; DHEA; DHEA S; Hormone replacement therapy

Indexed keywords

CYTOCHROME P450C17; ESTRADIOL; LIPID; PHOSPHOPROTEIN PHOSPHATASE; PLACEBO; PRASTERONE; PRASTERONE SULFATE; SOMATOMEDIN C; STEROID 17,20 LYASE; STEROID 17ALPHA MONOOXYGENASE; T LYMPHOCYTE RECEPTOR; TESTOSTERONE;

ADRENAL INSUFFICIENCY; ADULT; AGED; AGING; ARTICLE; ATHEROSCLEROSIS; DEMENTIA; DIABETES MELLITUS; DRUG EFFICACY; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME SPECIFICITY; FEMALE; HEALTH STATUS; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; LONGEVITY; MALE; OBESITY; OSTEOPOROSIS; PATIENT SATISFACTION; SEXUAL BEHAVIOR; T LYMPHOCYTE ACTIVATION; WELLBEING; PHYSIOLOGY;

AGING; DEHYDROEPIANDROSTERONE; HORMONE REPLACEMENT THERAPY; HUMANS;

EID: 1542315323     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.43.156     Document Type: Article

References (16)

1. Nawata H, Yanase T, Goto K, Okabe T, Ashida K. Mechanism of action of anti-aging DHEA-S and the replacement of DHEA-S. Mech Ageing Dev 123: 1101-1106, 2002.
2. Parker CR, Mixon RL, Brissie RM, Grizzle WE. Aging alters zonation in the adrenal cortex in men. J Clin Endocrinol Metab 82: 3898-3901, 1997.
3. Roth GS, Lane MA, Ingram DK, et al. Biomarkers of caloric restriction may predict longevity in humans. Science 297: 811, 2002.
4. Sunderland T, Merril CR, Harrington MG, et al. Reduced plasma dehydroepiandrosterone concentrations in Alzheimer's disease. Lancet ii: 570, 1989.
5. Yanase T, Fukahori M, Taniguchi S, et al. Serum dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEA-S) in Alzheimer's disease and in cerebrovascular dementia. Endocr J 43: 119-123, 1996.
6. Taniguchi S, Yanase T, Haji M, Ishibashi K, Takayanagi R, Nawata H. The antiobesity effect of dehydroepiandrosterone in castrated obese Zucker male rats. Obesity Res 3 suppl 5: 639S-643S, 1995.
7. Barrett-Connor E, Khaw K-T, Yen SSC. A prospective study of dehydroepiandrosterone sulfate, mortality and cardiovascular disease. N Engl J Med 315: 1519-1524, 1986.
8. Kroboth PD, Salek FS, Pittenger AL, Fabian TJ, Frye RF. DHEA and DHEA-S: A Review J Clin Pharmacol 39: 327-348, 1999.
9. Taniguchi S, Yanase T, Kobayashi K, Takayanagi R, Nawata H. Dehydroepiandrosterone markedly inhibits the accumulation of cholesteryl ester in mouse macrophage J-774-1 cells. Atherosclerosis 126: 143-154, 1996.
10. Nawata H, Tanaka S, Tanaka S, et al. Aromatase in bone cell: association with osteoporosis in postmenopausal women. J Steroid Biochem Molec Biol 53: 165-174, 1995.
11. Tanaka S, Haji M, Takayanagi R, Tanaka S, Sugioka Y, Nawata H. 1,25-dihydroxyvitamin D3 enhances the enzymatic activity and expression of the messenger ribonucleic acid for the aromatase cytochrome P450 synergistically with dexamethasone depending on the vitamin D receptor level in cultured human osteoblasts. Endocrinology 137: 1860-1869, 1996.
12. Okabe T, Haji M, Takayanagi R, et al. Up-regulation of high-affinity dehydroepiandrosterone binding activity by dehydroepiandrosterone in activated human T lymphocytes. J Clin Endocrinol Metab 80: 2993-2996, 1995.
13. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 78: 1360-1367, 1994.
14. Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 341: 1013-1020, 1999.
15. Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA 97: 4279-4284, 2000.
16. Labrie F, Diamond P, Cusan L, et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 82: 3498-3505, 1997.